Cervical Cancer

An analysis of global online conversations among health care professionals on social media in January showed celebration of the approval of a new drug for treatment of late-stage cervical cancer.

Rates of wellness visits and preventive health screenings remain below pre-COVID-19 pandemic levels, particularly among diverse groups, according to a recent study.

The FDA approved pembrolizumab in combination with chemoradiotherapy for the treatment of certain women with stage III to stage IVA cervical cancer.

Implementation of parent reminder/recall and health care professional audit/feedback increased HPV vaccination uptake compared with usual care approaches, according to study results published in JAMA Pediatrics.

Women who underwent active surveillance for cervical intraepithelial neoplasia grade 2 had an increased long-term risk for cervical cancer compared with women who received immediate treatment, according to findings published in The BMJ.

Aiming to address health disparities and inequities, the Biden administration announced the first-ever White House initiative to improve the way the United States approaches and funds women’s health research.

The addition of atezolizumab to bevacizumab and first-line chemotherapy improved PFS and OS compared with standard chemotherapy alone among women with metastatic, persistent or recurrent cervical cancer, study results showed.

HPV detectability was associated with better clinical cervical cancer prognosis vs. no detectable virus with up to a 41% lower mortality risk, according to a systematic review and meta-analysis published in Obstetrics & Gynecology.

MADRID — Induction chemotherapy prior to chemoradiation therapy improved outcomes for women with locally advanced cervical cancer, according to randomized phase 3 study results presented at ESMO Congress.